JP2019536783A - チロシン誘導体及びそれらを含む組成物 - Google Patents

チロシン誘導体及びそれらを含む組成物 Download PDF

Info

Publication number
JP2019536783A
JP2019536783A JP2019528632A JP2019528632A JP2019536783A JP 2019536783 A JP2019536783 A JP 2019536783A JP 2019528632 A JP2019528632 A JP 2019528632A JP 2019528632 A JP2019528632 A JP 2019528632A JP 2019536783 A JP2019536783 A JP 2019536783A
Authority
JP
Japan
Prior art keywords
cancer
tyrosine
methyl
composition
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019528632A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536783A5 (enExample
Inventor
ホフマン，スティーブン
Original Assignee
タイム，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/365,120 external-priority patent/US20170080093A1/en
Application filed by タイム，インコーポレーテッド filed Critical タイム，インコーポレーテッド
Publication of JP2019536783A publication Critical patent/JP2019536783A/ja
Publication of JP2019536783A5 publication Critical patent/JP2019536783A5/ja
Priority to JP2022122538A priority Critical patent/JP2022153587A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019528632A 2016-11-30 2017-11-30 チロシン誘導体及びそれらを含む組成物 Pending JP2019536783A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022122538A JP2022153587A (ja) 2016-11-30 2022-08-01 チロシン誘導体及びそれらを含む組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/365,120 2016-11-30
US15/365,120 US20170080093A1 (en) 2013-10-22 2016-11-30 Tyrosine Derivatives And Compositions Comprising Them
PCT/US2017/063865 WO2018102506A1 (en) 2016-11-30 2017-11-30 Tyrosine derivatives and compositions comprising them

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022122538A Division JP2022153587A (ja) 2016-11-30 2022-08-01 チロシン誘導体及びそれらを含む組成物

Publications (2)

Publication Number Publication Date
JP2019536783A true JP2019536783A (ja) 2019-12-19
JP2019536783A5 JP2019536783A5 (enExample) 2021-01-14

Family

ID=60703174

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019528632A Pending JP2019536783A (ja) 2016-11-30 2017-11-30 チロシン誘導体及びそれらを含む組成物
JP2022122538A Withdrawn JP2022153587A (ja) 2016-11-30 2022-08-01 チロシン誘導体及びそれらを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022122538A Withdrawn JP2022153587A (ja) 2016-11-30 2022-08-01 チロシン誘導体及びそれらを含む組成物

Country Status (12)

Country Link
EP (1) EP3548086A1 (enExample)
JP (2) JP2019536783A (enExample)
KR (1) KR20190089191A (enExample)
CN (1) CN110062633A (enExample)
AU (1) AU2017368135A1 (enExample)
BR (1) BR112019011033A2 (enExample)
CA (1) CA3045110A1 (enExample)
EA (1) EA201991305A1 (enExample)
IL (1) IL266840A (enExample)
MX (1) MX2019006326A (enExample)
PH (1) PH12019501186A1 (enExample)
WO (1) WO2018102506A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111743887A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 α-甲基酪氨酸或其衍生物的用途
WO2020232227A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
WO2021090069A1 (en) * 2019-11-07 2021-05-14 In3Bio Ltd. Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors
EP4090329A2 (en) * 2020-01-17 2022-11-23 Tyme, Inc. Tyrosine derivatives for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072800A1 (en) * 2004-02-02 2007-03-29 Stela Gengrinovitch Conjugates for cancer therapy and diagnosis
JP2009534381A (ja) * 2006-04-19 2009-09-24 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム 細胞画像化および治療のための組成物および方法
JP2016534071A (ja) * 2013-10-22 2016-11-04 タイム，インコーポレーテッド チロシン誘導体及びそれを含む組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
HUE027443T2 (en) * 2007-09-10 2016-10-28 Boston Biomedical Inc A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
KR102172658B1 (ko) * 2012-01-17 2020-11-02 타임, 인크. 약학 조성물 및 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070072800A1 (en) * 2004-02-02 2007-03-29 Stela Gengrinovitch Conjugates for cancer therapy and diagnosis
JP2009534381A (ja) * 2006-04-19 2009-09-24 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム 細胞画像化および治療のための組成物および方法
JP2016534071A (ja) * 2013-10-22 2016-11-04 タイム，インコーポレーテッド チロシン誘導体及びそれを含む組成物

Also Published As

Publication number Publication date
EA201991305A1 (ru) 2019-10-31
AU2017368135A1 (en) 2019-06-13
CA3045110A1 (en) 2018-06-07
KR20190089191A (ko) 2019-07-30
MX2019006326A (es) 2019-07-12
CN110062633A (zh) 2019-07-26
WO2018102506A1 (en) 2018-06-07
IL266840A (en) 2019-07-31
BR112019011033A2 (pt) 2019-10-15
EP3548086A1 (en) 2019-10-09
JP2022153587A (ja) 2022-10-12
PH12019501186A1 (en) 2020-02-10

Similar Documents

Publication Publication Date Title
US20220313642A1 (en) Tyrosine derivatives and compositions comprising them
US10307465B2 (en) Pharmaceutical compositions and methods
EP2804599B1 (en) Combination therapy for the treatment of cancer
US8481498B1 (en) Pharmaceutical compositions and methods
JP2022153587A (ja) チロシン誘導体及びそれらを含む組成物
US11052068B2 (en) Pharmaceutical compositions and methods
CA3040922A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
US20210106549A1 (en) Pharmaceutical compositions and methods
US11103559B2 (en) Pharmaceutical compositions and methods
US20210386832A1 (en) Pharmaceutical Compositions And Methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220331